L 668169 | CAS#137012-28-3 | tachykinin antagonist

MedKoo Cat#: 596621 | Name: L 668169

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L 668169 is a tachykinin antagonist.

Chemical Structure

L 668169

CAS#137012-28-3

Theoretical Analysis

MedKoo Cat#: 596621

Name: L 668169

CAS#: 137012-28-3

Chemical Formula: C82H108N16O14S2

Exact Mass: 1604.7672

Molecular Weight: 1605.98

Elemental Analysis: C, 61.33; H, 6.78; N, 13.95; O, 13.95; S, 3.99

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

L 668169; L-668169; L668169; L-668,169; L 668,169; L668,169;

IUPAC/Chemical Name

3,3'-(11,30-bis((1H-indol-3-yl)methyl)-14,33-dibenzyl-2,21-diisobutyl-13,32-dimethyl-5,24-bis(2-(methylthio)ethyl)-3,6,9,12,15,22,25,28,31,34,39,40-dodecaoxo-1,4,7,10,13,16,20,23,26,29,32,35-dodecaazatricyclo[34.2.1.117,20]tetracontane-8,27-diyl)dipropanamide

InChi Key

LRAVSBVSGQKVAS-UHFFFAOYSA-N

InChi Code

1S/C82H108N16O14S2/c1-47(2)39-67-77(107)89-59(33-37-113-7)73(103)87-57(27-29-69(83)99)71(101)93-64(44-52-46-86-56-26-18-16-24-54(52)56)80(110)96(6)66(42-50-21-13-10-14-22-50)76(106)92-62-32-36-98(82(62)112)68(40-48(3)4)78(108)90-60(34-38-114-8)74(104)88-58(28-30-70(84)100)72(102)94-63(43-51-45-85-55-25-17-15-23-53(51)55)79(109)95(5)65(41-49-19-11-9-12-20-49)75(105)91-61-31-35-97(67)81(61)111/h9-26,45-48,57-68,85-86H,27-44H2,1-8H3,(H2,83,99)(H2,84,100)(H,87,103)(H,88,104)(H,89,107)(H,90,108)(H,91,105)(H,92,106)(H,93,101)(H,94,102)

SMILES Code

CC(CC1C(NC(CCSC)C(NC(CCC(N)=O)C(NC(Cc2c3ccccc3[nH]c2)C(N(C)C(Cc4ccccc4)C(NC5CCN(C(CC(C)C)C(NC(CCSC)C(NC(CCC(N)=O)C(NC(Cc6c7ccccc7[nH]c6)C(N(C)C(Cc8ccccc8)C(NC9CCN1C9=O)=O)=O)=O)=O)=O)C5=O)=O)=O)=O)=O)=O)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,605.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tao YX, Zhao ZQ. [Neurokinin-1 receptor mediated formalin-induced c-fos expression in the rat spinal cord]. Sheng Li Xue Bao. 1998 Aug;50(4):361-6. Chinese. PubMed PMID: 11324543. 2: Tao YX, Wei F, Zhao ZQ. A contribution of neurokinin-1 receptor to formalin-induced c-fos expression in the rat spinal dorsal horn. Neurosci Lett. 1997 Jan 17;221(2-3):105-8. PubMed PMID: 9121675. 3: Lebrun CJ, Wende P, Steckelings U, Itoi K, Unger T. Effects of tachykinins on phosphoinositide metabolism in the hypothalamus: is the NK1 receptor involved? Brain Res. 1993 Dec 31;632(1-2):74-9. PubMed PMID: 7511982. 4: Seabrook GR, Main MJ, Razzaque Z, Longmore J. Differences in the effects of tachykinin NK1 receptor antagonists: neuronal versus smooth muscle tissues. Eur J Pharmacol. 1993 Nov 30;250(1):125-31. PubMed PMID: 7509748. 5: Parker RM, Fleetwood-Walker SM, Rosie R, Munro FE, Mitchell R. Inhibition by NK2 but not NK1 antagonists of carrageenan-induced preprodynorphin mRNA expression in rat dorsal horn lamina I neurons. Neuropeptides. 1993 Oct;25(4):213-22. PubMed PMID: 7902962. 6: Razzaque Z, Longmore J. Comparison of the effects of (+/-) CP 96,345 and L-668,169 on neurokinin receptor mediated responses in rat and guinea-pig isolated tissues. Neuropeptides. 1993 Sep;25(3):169-74. PubMed PMID: 7504215. 7: Kunitomo M, Imaizumi N, Sameshima E, Fujiwara M. Pharmacological analysis of receptors involved in tachykininergic contraction induced by electrical transmural stimulation in the rabbit iris sphincter muscle. Regul Pept. 1993 Jul 2;46(1-2):282-4. PubMed PMID: 7692516. 8: Kunitomo M, Imaizumi N, Sameshima E, Fujiwara M. Pharmacological analysis of receptors involved in the late, tachykininergic contractile response to electrical transmural stimulation in isolated rabbit iris sphincter muscle. Jpn J Pharmacol. 1993 Jul;62(3):257-61. PubMed PMID: 7692119. 9: Morbidelli L, Maggi CA, Ziche M. Effect of selective tachykinin receptor antagonists on the growth of human skin fibroblasts. Neuropeptides. 1993 Jun;24(6):335-41. PubMed PMID: 7688874. 10: Wollborn U, Brunne RM, Harting J, Hölzemann G, Leibfritz D. Comparative conformational analysis and in vitro pharmacological evaluation of three cyclic hexapeptide NK-2 antagonists. Int J Pept Protein Res. 1993 Apr;41(4):376-84. PubMed PMID: 8388367. 11: Patacchini R, Santicioli P, Astolfi M, Rovero P, Viti G, Maggi CA. Activity of peptide and non-peptide antagonists at peripheral NK1 receptors. Eur J Pharmacol. 1992 Apr 29;215(1):93-8. PubMed PMID: 1381319.